Recent News

• 09.10.2025 - Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing
• 08.20.2025 - Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
• 08.15.2025 - Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
• 08.14.2025 - Tivic Reports Second Quarter 2025 Financial Results

Recent Filings

• 09.05.2025 - EFFECT Notice of Effectiveness
• 09.05.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.29.2025 - S-3 Registration statement under Securities Act of 1933
• 08.27.2025 - 8-K Current report
• 08.22.2025 - 4/A Statement of changes in beneficial ownership of securities
• 08.22.2025 - 4/A Statement of changes in beneficial ownership of securities
• 08.22.2025 - 4/A Statement of changes in beneficial ownership of securities
• 08.20.2025 - 8-K Current report
• 08.20.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 8-K Current report